Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.